{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:25:15Z","timestamp":1765545915344},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T00:00:00Z","timestamp":1410220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00280-014-2580-z","type":"journal-article","created":{"date-parts":[[2014,9,8]],"date-time":"2014-09-08T06:53:59Z","timestamp":1410159239000},"page":"1029-1032","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts"],"prefix":"10.1007","volume":"74","author":[{"given":"Philip M.","family":"Tedeschi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamini K.","family":"Kathari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iqra N.","family":"Farooqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Bertino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,9]]},"reference":[{"key":"2580_CR1","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1016\/S0021-9258(19)70697-8","volume":"255","author":"JJ McGuire","year":"1980","unstructured":"McGuire JJ, Hsieh P, Coward JK, Bertino JR (1980) Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J Biol Chem 255:5776\u20135788","journal-title":"J Biol Chem"},{"key":"2580_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.1981.tb07237.x","volume":"49","author":"BA Kamen","year":"1981","unstructured":"Kamen BA, Nylen PA, Camitta BM, Bertino JR (1981) Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 49:355\u2013360. doi: 10.1111\/j.1365-2141.1981.tb07237.x","journal-title":"Br J Haematol"},{"key":"2580_CR3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0006-2952(66)90022-0","volume":"15","author":"DG Johns","year":"1966","unstructured":"Johns DG, Iannotti AT, Sartorelli AC, Bertino JR (1966) The relative toxicites of methotrexate and aminopterin. Biochem Pharmacol 15:555\u2013561","journal-title":"Biochem Pharmacol"},{"key":"2580_CR4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00280-013-2231-9","volume":"72","author":"M Visentin","year":"2013","unstructured":"Visentin M, Unal ES, Zhao R, Goldman ID (2013) The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor. Cancer Chemother Pharmacol 72:597\u2013606. doi: 10.1007\/s00280-013-2231-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"2580_CR5","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.1158\/1078-0432.CCR-12-2251","volume":"19","author":"E Marchi","year":"2013","unstructured":"Marchi E, Mangone M, Zullo K, O\u2019Connor OA (2013) Pralatrexate pharmacology and clinical development. Clin Cancer Res Off J Am Assoc Cancer Res 19:6657\u20136661. doi: 10.1158\/1078-0432.CCR-12-2251","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2580_CR6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00280-009-0954-4","volume":"64","author":"E Izbicka","year":"2009","unstructured":"Izbicka E, Diaz A, Streeper R et al (2009) Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers. Cancer Chemother Pharmacol 64:993\u2013999. doi: 10.1007\/s00280-009-0954-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"2580_CR7","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1172\/JCI106181","volume":"48","author":"WM Hryniuk","year":"1969","unstructured":"Hryniuk WM, Bertino JR (1969) Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 48:2140\u20132155","journal-title":"J Clin Invest"},{"key":"2580_CR8","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3109\/10428194.2013.779688","volume":"54","author":"E Koch","year":"2013","unstructured":"Koch E, Story SK, Geskin LJ (2013) Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy. Leuk Lymphoma 54:2448\u20132451. doi: 10.3109\/10428194.2013.779688","journal-title":"Leuk Lymphoma"},{"key":"2580_CR9","first-page":"1433","volume":"29","author":"I Ahmed","year":"2013","unstructured":"Ahmed I, Ahmed Tipu S, Ishtiaq S (2013) Malignant mesothelioma. Pak J Med Sci 29:1433\u20131438","journal-title":"Pak J Med Sci"},{"key":"2580_CR10","first-page":"3553","volume":"33","author":"CCLM Boons","year":"2013","unstructured":"Boons CCLM, VAN Tulder MW, Burgers JA et al (2013) The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer Res 33:3553\u20133561","journal-title":"Anticancer Res"},{"key":"2580_CR11","first-page":"319","volume":"110","author":"V Neumann","year":"2013","unstructured":"Neumann V, L\u00f6seke S, Nowak D et al (2013) Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. Dtsch \u00c4rztebl Int 110:319\u2013326. doi: 10.3238\/arztebl.2013.0319","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"2580_CR12","first-page":"317","volume":"2","author":"LM Krug","year":"2007","unstructured":"Krug LM, Heelan RT, Kris MG et al (2007) Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 2:317\u2013320. doi: 10.1097\/01.JTO.0000263715.84567.5f","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"2580_CR13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00280-014-2441-9","volume":"73","author":"M Visentin","year":"2014","unstructured":"Visentin M, Unal ES, Goldman ID (2014) The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro. Cancer Chemother Pharmacol 73:1055\u20131062. doi: 10.1007\/s00280-014-2441-9","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2580-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2580-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2580-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T14:23:35Z","timestamp":1650119015000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2580-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,9]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["2580"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2580-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,9]]}}}